IL DONG PHARMACEUTICAL CO., LTD.
Financials
Valuation Metrics
IL DONG PHARMACEUTICAL CO., LTD.'s Market Cap is ₩4705B. At end of 2025 it was ₩1.2T. Ranked #507 of 2,419 in KR market (top 21%), #307 of 781 on KOSPI (top 39%), #56 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 24%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 470.46B KRW | KR#507/2,419 Sec#56/231 |
| Revenue | 582.33B KRW | KR#569/2,419 Sec#27/231 |
| Net Income | 39.57B KRW | KR#490/2,419 Sec#30/231 |
| Total Assets | 573.03B KRW | KR#711/2,419 Sec#40/231 |
| Net Assets | 239.51B KRW | KR#844/2,419 Sec#55/231 |
| Employees | 1,056 | KR#245/2,419 Sec#16/231 |
| Value | ||
| P/E | 11.89x | KR#904/2,419 Sec#49/231 |
| P/B | 1.96x | KR#1,894/2,419 Sec#136/231 |
| PEG | 0.03x | KR#246/2,419 Sec#15/231 |
| P/S | 0.81x | KR#1,224/2,419 Sec#65/231 |
| EV/EBITDA | 20.48x | KR#1,015/2,419 Sec#60/231 |
| FCF Yield | 1.13% | KR#1,122/2,419 Sec#80/231 |
| Profitability | ||
| ROE | 16.52% | KR#254/2,419 Sec#15/231 |
| ROA | 6.91% | KR#530/2,419 Sec#42/231 |
| Op. Margin | 4.45% | KR#1,033/2,419 Sec#75/231 |
| Revenue Growth | -0.65% | KR#1,569/2,419 Sec#156/231 |
| Earnings Growth | 384.27% | KR#133/2,419 Sec#7/231 |
| Financial Health | ||
| Debt Ratio | 139.25% | KR#1,849/2,419 Sec#204/231 |
| Total Debt | 124.63B KRW | KR#656/2,419 Sec#39/231 |
| FCF | 5.30B KRW | KR#887/2,419 Sec#62/231 |
| Cash | 64.85B KRW | KR#636/2,419 Sec#33/231 |
| Current Ratio | 1.00x | KR#1,721/2,419 Sec#172/231 |
| Net Debt/EBITDA | 2.31x | KR#861/2,419 Sec#62/231 |
| Dividend | ||
| Div. Yield | 1.35% | KR#1,019/2,419 Sec#54/231 |
| Performance | ||
| 1Y Return | -45.33% | KR#2,024/2,419 Sec#183/231 |
| 1M Return | -1.13% | KR#1,328/2,419 Sec#138/231 |
| From 52W High | -66.99% | KR#2,137/2,419 Sec#186/231 |
| 1Y MDD | -72.57% | KR#2,093/2,419 Sec#183/231 |
| Trading | ||
| Volume | 184,082 shares | KR#553/2,419 Sec#68/231 |
| Trading Value | 2.75B KRW | KR#504/2,419 Sec#65/231 |
| Foreign Own. | 5.34% | KR#815/2,419 Sec#75/231 |
| Per Share | ||
| EPS | 1,251 KRW | KR#632/2,419 Sec#42/231 |
| BPS | 7,570 KRW | KR#1,173/2,419 Sec#85/231 |
Company Info
Established in 2016, this company manufactures and sells pharmaceuticals, raw materials, and health supplements. Its main products include the active vitamin AROAMIN series and the antibiotic FULUMARIN, which are sold domestically and internationally through various channels. The company conducts R&D for metabolic and respiratory disease treatments, with its COVID-19 treatment ID32124 (Xocova) having received approval in Japan, advancing its global new drug development and commercialization. Ildong Pharmaceutical was founded in 2016 and is headquartered in Seocho-gu, Seoul.